• 생명과학회지
• /
• 제15권1호
• /
• pp.1-8
• /
• 2005

이황화메틸의 반복 흡입노출에 의한 아급성 독성 잠재력을 평가하기 위해 암수 랫드에게 0, 5, 25 및 125 ppm용량으로 21일간 반복 흡입노출하고, 일반증상과 체중, 사료섭취 량, 혈액치, 혈청생화학치 및 부검소견을 관찰하였다. 시험결과, 랫드에게 이황화메틸을 3주간 반복 흡입노출하면 125 ppm의 농도에서 체중증가의 억제와 사료섭취 량의 감소를 유발하나, 혈액 및 혈청생화학치에는 어떠한 이상도 유발하지 않는 것으로 나타났다. 본 시험 조건 하에서 이황화메틸의 표적 장기는 관찰되지 않았으며, 무해용량은 암수 모두 25 ppm으로 사료된다.

• 한국독성학회:학술대회논문집
• /
• 한국독성학회 2003년도 춘계학술대회 논문집
• /
• pp.43-44
• /
• 2003

The subacute toxicity and toxicokinetics of a type IV phosphodiesterase inhibitor, CJ-10882, were evaluated after single (on the 1st day) and 4-week (on the 27th day) oral administration of the drug, in doses of 0 (to serve as a control), 2, 10 and 50 mg/kg/d, to male and female dogs (n = 3 for male and female dogs for each dose). During the test period, clinical signs, mortality, body weight, food consumption, ophthalmoscopy, urinalysis, hematology, serum biochemistry, gross findings, organ weight and histopathology were examined.(omitted)

• 한국약용작물학회지
• /
• 제26권2호
• /
• pp.157-169
• /
• 2018

Background: Cassia tora L., an annual or perennial plant of the Fabaceae family, is traditional medicine with various biological activities, including anti-constipation and, anti-inflammation. Chemical compounds such as anthraquinone glycoside and naphthalene derivatives have been isolated from this plant. Cassia tora L. is a common contaminant of agricultural commodities, but is toxic to cattle and poultry. Methods and Results: To investigate the potential toxicity, Cassia tora L. aqueous extract (CO) was administered orally to rats for 26 weeks at 0 (control), 300, 1,500 and 3,000 mg/kg/day (n = 10 for male rats for each dose). The positive control comprised animals orally administered anthraquinone 100 mg/kg/day. There was no treatment-related mortality. An increase in the kidney weight was observed at 3,000 mg/kg/day of CO and anthraquinone 100 mg/kg/day. Macrophage infiltration in the colon was observed at CO 1,500 and 3,000 mg/kg/day and anthraquinone 100 mg/kg/day, but there were no significant toxicological changes in the incidence and severity of the finding. Conclusions: The oral no-observed-adverse-effect level (NOAEL) of CO was 3,000 mg/kg/day in male rats and no target organs were identified. In addition, 300 mg/kg was found to be the no-observed-effect level (NOEL) for systemic toxicity under the conditions of the study.

• 한국가스학회지
• /
• 제21권1호
• /
• pp.6-17
• /
• 2017

본 연구는 3-methylpentane에 대한 흡입유해성을 평가하여 국제연합에서 정하는 화학물질의 분류 및 표지에 관한 세계조화시스템(Globally harmonized system, GHS)지침 및 고용노동부고시 제2013-37호에 따른 3-methylpentane의 화학물질 분류 표시 자료를 생산하기 위하여 OECD 화학물질 시험가이드라인 아급성흡입독성시험 TG 412(Subacute inhalation toxicity) 시험법에 따라 수행하였다. 본 연구를 위하여 6주령의 랫드(Rat)를 도입하여 1주간 순화시킨 후 암수 각각 대조군 5마리, 저농도군(284 ppm) 5마리, 중농도군(1,135 ppm) 5마리, 고농도군(4,540 ppm) 5마리 등으로 군을 구성하여 일일 6시간, 주 5일, 4주 동안 시험물질을 랫드에 전신으로 노출시켰다. 시험물질 노출을 종료하고 2주 후 시험동물을 희생하여 시험물질에 의한 시험동물의 영향을 평가하였다. 사료섭취량 변화, 체중 변화, 임상관찰, 혈액검사, 부검 소견, 장기무게 측정, 조직병리검사 등 모든 시험결과에서 시험물질에 의한 영향은 나타나지 않아 3-methylpentane의 무유해영향농도는 암수 모두 4,540 ppm이상으로 판단되어 세계조화시스템(GHS) 지침 및 고용노동부고시 제2013-37호(화학물질의 분류 표시 및 물질안전보건에 관한 기준)의 특정표적장기독성(반복노출) 구분 표시 물질에 해당하지 않은 물질로 판단되었다.

• Environmental Analysis Health and Toxicology
• /
• 제25권2호
• /
• pp.131-143
• /
• 2010

We performed the tests of acute and subchronic inhalation toxicity of methyl formate, which has limited toxicological data in spite of its widespread use and enhanced hazard consequent on its high volatility. The median lethal concentration ($LC_{50}$) was evaluated to be above 5,000ppm(12.27 mg/L). In the test with subchronic inhalation, there are no deaths, but with reduction of body weight, food intake, organ weight by exposure to 400 (0.98 mg/L) and 1,600 (3.92 mg/L) ppm, dose-dependently. There were statistical differences in some hematological and blood biochemical parameters as compared to control (e.g. neutrophile and lymphocyte in the 1,600 ppm group, calcium and A/G in 1,600 ppm group). Methyl formate under the exposure of 1,600 ppm showed the respiratory findings with nasal, it was confirmed that the chemical has respiratory hazard with 1,600 ppm inhalation exposure, induces nasal epithelial atrophy, olfactory cell degeneration/regeneration and the contraction of olfactory cells, etc. According to the notification with Ministry of Labor (No. 2009-68) for classification, labeling and MSDS of chemicals, it is suggested for methyl formate to be classified as category 4 in acute (10.0$4\leq20.0$ mg/L), category 2 (0.2$\leq$1.0 mg/L/6h, 90 days) in specific target organ-repeated exposure.

• 한국환경농학회지
• /
• 제33권4호
• /
• pp.395-402
• /
• 2014

님추출물은 유효성분(active ingredient)으로 azadirachtin을 함유하여 전세계적으로 충해방제용 유기농업자재로 널리 사용되고 있다. 그러나, 님추출물은 님 원료부위 및 추출용매에 따라 종류가 매우 다양하고 안전성에 크게 차이가 난다고 보고되고 있다. 본 연구에서는 우리나라에서 유기농업자재 제품의 원제로 사용되는 수용성 님추출물이 주요 독성기관인간에 미치는 영향에 대해서 살펴보고자 SD 랫드를 이용하여 4주 반복경구독성시험을 수행하였다. 시험결과, 님추출물 시험물질의 투여 농도가 증가함에 따라 간의 상대중량이 증가하였다(p <0.05). 혈액 생화학분석 결과, 수컷에서 대조군에 비해 시험물질 처리시 혈중 LDH는 감소하였으나 GOT와 GPT가 증가하였으며(p <0.05), 특히 GPT가 시험물질에 농도 의존적으로 증가함에 따라 수컷에서 간 손상의 가능성을 나타내었다. 또한, 고농도로 님추출물 시료를 처리한 경우 수컷의 혈중 GGT가 급격히 증가하였으며 혈중 GLU도 유의적으로 증가하였으나(p <0.05), 뇨 중 GLU는 님추출물의 처리농도증가에 따른 변화가 나타나지 않았다. 간의 조직병리학적 변화를 살펴본 결과 님추출물 시료 처리에 따른 간의 병변도 확인되지 않았다. 따라서 본 시험에 사용된 수용성 님추출물 시료는 혈액 생화학적 분석 결과 수컷에서 간손상의 가능성은 있었으나 조직병리학적 변화는 관찰되지 않았다. 따라서, 수용성 님추출물 2.0 g/Kg 을 4주간 랫드에 경구투여한 결과 간에 독성을 미치지 않고 안전한 것으로 판단된다.

• 한국식품영양학회지
• /
• 제26권3호
• /
• pp.383-390
• /
• 2013

본 연구에서는 겨우살이 열수 추출물인 미슬로 C의 안전성을 검토하고자 유전 독성 및 실험동물을 이용한 안전성 검사를 실시하였다. 미슬로 C의 미생물 돌연변이 실험을 S. typhimurium의 히스티딘 요구성 균주와 E. coli의 트립토판 요구성 균주를 이용하여 대사 활성계 적용 및 비적용 하에서 복귀돌연변이 시험을 실시한 바, $5,000{\mu}g/plate$의 처리 농도까지 복귀돌연변이 집락은 나타나지 않았다. ICR 마우스에게 500, 1,000 및 2,000 mg/kg를 경구 투여하고, 골수세포를 수집하여 소핵을 측정한 결과, 정상마우스의 경우와 비교하여 유의한 소핵은 관찰되지 않았기에 미슬로 C는 유전독성을 유발하지 않는 것으로 판단되었다. 식품의약안전청의 의약품 등의 독성시험기준에 따라 암 수 SD 계열의 랫드에 시험물질을 0, 500, 1,000 및 2,000 mg/kg/day의 용량으로 1회 경구 투여한 후, 14일간의 체중 변화 및 사망률을 조사한 결과, 대조군과 비교하여 유의한 체중 변화는 없었으며, $LD_{50}$은 2,000 mg/kg 이상인 것으로 사료된다. 또한 0, 250, 500 및 1,000 mg/kg/day의 용량으로 13주간 반복 투여하면서 실험동물의 일반증상, 체중변화, 혈액 및 혈액생화학적 변화, 부검소견, 조직학적인 변화를 관찰하였다. 시험기간 중 암 수 모든 군에서 시험물질 투여에 기인한 일반적인 증상 변화는 관찰되지 않았고, 시험물질의 반복 투여로 인한 사망 마우스 역시 관찰되지 않았다. 따라서 미슬로 C를 13주간의 랫드에 대한 13주 반복 경구 투여 결과, 무독성량은 최소한 1,000 mg/kg 이하인 결과를 나타냈으며, 이 농도에서 독성을 유발하는 표적장기는 관찰되지 않았다.

• 대한수의학회지
• /
• 제44권4호
• /
• pp.523-532
• /
• 2004

The present study was carried out to investigate the potential adverse effects of amitraz on pregnant dams after maternal exposure during the gestational days (GD) 1 through 19 in Sprague-Dawley rats. The test chemical was administered orally to pregnant rats at dose levels of 0, 3, 10, or 30 mg/kg/ day. During the test period, clinical signs, mortality, body weights, food consumption, serum biochemistry, gross findings, organ weights and reproductive findings on GD 20 were examined. In the 30 mg/kg group, an increase in the incidence of abnormal clinical signs and death, a suppression in the body weight gain, and a decrease in the food consumption were observed. A decrease in the liver weight and increases in the kidneys, adrenal glands and heart weights were also found. Serum biochemical investigations revealed increases in the aspartate aminotransferase (AST), total bilirubin, and chloride. In addition, an increase in the fetal death and decreases in the litter size and fetal body weight were seen at caesarean section. Inthe 10 mg/kg group, an increase in the incidence of abnormal clinical signs, decreases in the food consumption and liver weight, increases in the total bilirubin and chloride, and a decrease in the fetal body weight were observed. There were no adverse effects on clinical signs, mortality, body weights, food consumption, serum biochemistry, gross findings, organ weights and reproductive findings in the 3 mg/kg group. Based on the results, it was concluded that the 19-day repeated oral dose of amitraz to pregnant rats caused increases in the clinical signs, kidneys, adrenal glands and heart weights, AST, total bilirubin and chloride and decreases in the body weight gain, food consumption and liver weight at the dose levels of above 10 mg/kg/day. Under the present experimental conditions, the no-observed-adverse-effect level (NOAEL) of amitraz was considered to be 3 mg/kg/day.

• 대한한의학회지
• /
• 제30권3호
• /
• pp.79-85
• /
• 2009

Aim : To evaluate the pharmaceutical safety of the herbal formula Myelophil, composed of Astragali Radix and Salviae Radix, via systemic subacute toxicological study using SD rats. Methods : Forty male and 40 female SD rats were fed with Myelophil (5000, 2500 or 1250 mg/10 mL/kg) or distilled water for four weeks. Adverse effects were examined intensively by comparing the differences between normal and drug-administered groups using clinical signs, necropsies, histopathologic findings, hematology, urinalysis, and blood biochemical analysis. Results : No altered clinical symptoms including body weight, diarrhea, anorexia, death, and abnormal necropsy of major organs were observed in male or female rats. No drug-induced abnormalities in histopathological finding, hematological values, urinalysis, and blood biochemical values were found at any doses of Myelophil. Conclusion : Myelophil should be very safe when used in a clinical application with a wide therapeutic index.

• Biomolecules & Therapeutics
• /
• 제21권1호
• /
• pp.84-88
• /
• 2013

High risk of cardiovascular diseases caused by existing PPAR-${\gamma}$ agonists such as rosiglitazone and pioglitazone has been recently reported. CKD-501 is a novel selective PPAR-${\gamma}$ agonist as a potential target to reduce cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). In this study, We investigated potential cardiotoxicity of CKD-501 and compared its toxicity with that of rosiglitazone or pioglitazone using db/db mice. After 12-week repeated administration of CKD-501 at doses of 3, 10 and 30 mg/kg/day or rosiglitazone at doses of 10 and 30 mg/kg/day or pioglitazone at doses of 200 and 540 mg/kg/day, animals were sacrificed for investigation of potential toxicities. Diameters of left ventricles and areas of cardiomyocytes were measured. And lipid accumulation and apoptosis in heart muscle were examined by oil red O staining and TUNEL staining, respectively. Diameters of left ventricles were significantly increased in high dose treatment group of pioglitazone compared to control (p<0.05), while other groups showed a tendency for an increase. All test articles induced significantly the increase of area of cardiomyocytes in heart compared to control (p<0.01), in regular order as pioglitazone > CKD-501 ${\geq}$ rosiglitazone. However, lipid accumulation and apoptotic changes in heart were not observed in all dosing groups. Taken together, the myocardial cell hypertrophy of CKD-501 are relatively lower than that of pioglitazone and similar to rosiglitazone. And it is suggested that the myocardial cell hypertrophy of CKD-501 are less adverse in clinical use for the management of the NIDDM.